Clinical Trials Browser

Phase 2 × Withdrawn × siltuximab × Clear all

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Cytokine Release Syndrome, Multiple Myeloma

NCT00311545 2013-02-20

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms